Introduction
============

Lung cancer is the most common cancer, and the fifth most common cause of death worldwide, primarily because of high invasion, metastasis, and drug resistance ([@b1-or-0-0-7314],[@b2-or-0-0-7314]). Approximately 85% of all lung cancer cases are classified as non-small cell lung cancer (NSCLC), including adenocarcinoma (Ade) and squamous cell carcinoma (SCC) subtypes ([@b3-or-0-0-7314]). Although multidisciplinary therapies are widely used to treat NSCLC, its overall prognosis remains very poor. In addition, currently there is no standard method to predict the survival of patients with NSCLC ([@b4-or-0-0-7314]). Hence, there is an urgent need for novel and effective prognostic biomarkers for NSCLC.

Insulin-like growth factors (IGFs) are peptide ligands that regulate cellular proliferation, differentiation, apoptosis, and carcinogenesis ([@b5-or-0-0-7314],[@b6-or-0-0-7314]). IGF binding proteins (IGFBPs) are circulating proteins that modulate IGF signaling by sequestering the circulating IGFs, thereby regulating the mitogenic activity of the IGF receptors ([@b7-or-0-0-7314]). The conventional IGFBP family has six members (IGFBP1-6), which bind IGFs with high affinity ([@b8-or-0-0-7314]). However, the concept of IGFBPs has recently been redefined to include proteins that increase the half-life of IGFs. Now, at least 10 members of the IGFBP superfamily have been identified, including proteins that bind IGFs with low affinity ([@b9-or-0-0-7314]). Recently, conventional IGFBPs have attracted increased attention due to their roles in NSCLC. Previous studies have demonstrated abnormal expression of IGFBPs in NSCLC, and assessed the diagnostic roles of circulating IGFBP concentrations in the disease ([@b10-or-0-0-7314]--[@b17-or-0-0-7314]). However, the prognostic roles of individual IGFBPs in NSCLC, particularly at the mRNA level, remain unknown.

The development of microarray and RNA-sequencing technology has revolutionized RNA and DNA research, providing a wealth of data for bioinformatic analysis. In the present study, data mining analysis was performed from patients with NSCLC using various tools, with the purpose of exploring the differential expression, potential functions, and distinct prognostic values of IGFBP family members in NSCLC.

Materials and methods
=====================

### Gene expression profiling analysis

Gene Expression Profiling Interactive Analysis (GEPIA; <http://gepia.cancer-pku.cn>) is a newly developed interactive web server for the analysis of RNA sequencing data derived from 9,736 tumors and 8,587 healthy samples from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets. GEPIA provides customizable functions including differential expression analysis, profile plotting, correlation analysis, patient survival analysis, detection of similar genes, and dimensionality reduction analysis ([@b18-or-0-0-7314]). The expression of IGFBPS between tumor and normal tissues was analyzed using Student\'s t-test, and expression of IGFBPs in different tumor stages of NSCLC was analyzed using F-test. P\<0.01 and fold change (FC)\>2 were considered significant. In addition, IGFBP protein levels were analyzed using the Human Protein Atlas database (HPA) (<https://www.proteinatlas.org/>) to confirm whether the expression at the mRNA and protein levels matched ([@b19-or-0-0-7314]).

### Prognostic analysis

The prognostic value of the mRNA expression of IGFBP family members was evaluated using an online tool, Kaplan-Meier Plotter ([www.kmplot.com](www.kmplot.com)) and GEPIA (<http://gepia.cancer-pku.cn>). To analyze the overall survival (OS) of patients with NSCLC, patient samples were divided into two groups (low and high expression) based on median mRNA levels with a hazard ratio (HR) with 95% confidence intervals (CI) and log-rank P-values ([@b20-or-0-0-7314]). Log-rank P-values \<0.05 were considered statistically significant. Univariate cox analysis was conducted with adjustments to smoking status, clinical stages, chemotherapy, and sex of NSCLC.

### Analysis of gene alteration frequency

Known alterations in IGFBP genes in patients with NSCLC were obtained from the cBioPortal for Cancer Genomics (<http://www.cbioportal.org>) ([@b21-or-0-0-7314]). Genomic profiles, including mutations, putative copy-number alterations, and mRNA expression levels, were selected by querying individual IGFBP family members.

### Functional enrichment and bioinformatics analysis

GeneMANIA (<http://www.genemania.org>), a prediction server that acts as a biological network integrator for gene prioritization and function prediction ([@b22-or-0-0-7314]), was used for correlation analysis of IGFBP family members at the gene level. Enrichment analysis for gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways ([@b23-or-0-0-7314],[@b24-or-0-0-7314]) was performed in the Database for Annotation, Visualization and Integrated Discovery (DAVID; version 6.7, <http://david.ncifcrf.gov/tools.jsp>).

Results
=======

### IGFBP mRNA levels in patients with NSCLC

The relative mRNA expression of IGFBP genes in Ade and SCC were examined, and compared to healthy tissue using GEPIA analysis. Compared to healthy lung tissues, IGFBP2 mRNA expression was significantly higher in SCC tissues, IGFBP3 mRNA expression was significantly higher in both Ade and SCC tissues, and IGFBP6 mRNA expression was significantly lower in both NSCLC subtypes. Differences in expression between lung cancer and healthy tissues were not observed for other IGFBPs ([Fig. 1A](#f1-or-0-0-7314){ref-type="fig"}). IGFBP expression was also investigated in different stages of NSCLC. Only IGFBP1 expression changed significantly across various tumor stages, whereas, the rest of the expression levels of IGFBPs in various tumor stages were not differential ([Fig. 1B](#f1-or-0-0-7314){ref-type="fig"}). Additionally, the mRNA expression levels of IGFBP1, IGFBP4, and IGFBP6 matched their reported protein expression levels. However, representative images of the IGFBP2, IGFBP3, and IGFBP5 protein levels were not available in the HPA database ([Fig. 2](#f2-or-0-0-7314){ref-type="fig"}).

### Prognostic value of IGFBP mRNA levels in NSCLC

Next, the prognostic significance of IGFBP levels were assessed, both in the total NSCLC cohort and in the Ade and SCC subtypes, using Kaplan-Meier analysis. For the complete cohort, increase in IGFBP1, IGFBP2, and IGFBP4 mRNA was strongly associated with unfavorable OS, while IGFBP3, IGFBP5, and IGFBP6 mRNA levels were not significantly correlated with the OS ([Fig. 3](#f3-or-0-0-7314){ref-type="fig"}). Increased IGFBP1, IGFBP2, and IGFBP4 mRNA levels were correlated with unfavorable OS in patients with Ade, while IGFBP3, IGFBP5 and IGFBP6 mRNA levels were not associated with the OS ([Fig. 4](#f4-or-0-0-7314){ref-type="fig"}). Additionally, increased IGFBP2 and IGFBP5 mRNA levels were correlated with favorable OS in SCC patients, while the mRNA levels of other IGFBPs were not significantly correlated with the OS ([Fig. 5](#f5-or-0-0-7314){ref-type="fig"}). Notably, these results indicated that IGFBP2 plays different prognostic roles in Ade and SCC. The prognostic values of IGFBP family members were validated using the NSCLC data available in GEPIA. As revealed in [Fig. 6](#f6-or-0-0-7314){ref-type="fig"}, increased IGFBP1 and IGFBP3 mRNA was correlated with unfavorable OS in NSCLC patients, while other IGFBPs were not significantly correlated with the OS.

### Prognostic values of IGFBP levels in NSCLC subsets with different clinicopathological features

To assess for correlations between IGFBP expression and other clinicopathological features, the smoking status ([Table I](#tI-or-0-0-7314){ref-type="table"}), clinical stages ([Table II](#tII-or-0-0-7314){ref-type="table"}), chemotherapy treatments ([Table III](#tIII-or-0-0-7314){ref-type="table"}), and sex ([Table IV](#tIV-or-0-0-7314){ref-type="table"}) of patients with NSCLC were examined. High IGFBP2, IGFBP3, and IGFBP4 mRNA levels were associated with unfavorable OS in patients who had never smoked, while high IGFBP1 and IGFBP4 mRNA levels were associated with unfavorable OS in patients with a history of smoking ([Table I](#tI-or-0-0-7314){ref-type="table"}). These results indicated that the prognostic role of *IGFBP4* in NSCLC is independent of the smoking status.

High IGFBP1, IGFBP2, and IGFBP4 mRNA levels were significantly correlated with unfavorable OS in patients with stage I NSCLC ([Table II](#tII-or-0-0-7314){ref-type="table"}), and high IGFBP2 and IGFBP4 mRNA levels were associated with unfavorable OS in stage II NSCLC. These results indicated that *IGFBP1, IGFBP2*, and *IGFBP4* have prognostic roles in early-stage NSCLC. Increased IGFBP5 mRNA was significantly associated with unfavorable OS in patients who did not receive chemotherapy ([Table III](#tIII-or-0-0-7314){ref-type="table"}). Moreover, increased levels of IGFBP1 mRNA were significantly associated with unfavorable OS in female patients, and increased IGFBP2 mRNA levels were significantly associated with unfavorable OS in male patients. Increased IGFBP4 mRNA levels were significantly associated with unfavorable OS in both female and male patients ([Table IV](#tIV-or-0-0-7314){ref-type="table"}).

### IGFBP alterations in NSCLC

The genetic alterations present in IGFBPs were analyzed in NSCLC using cBioPortal. Thirteen NSCLC datasets were analyzed. Among the datasets analyzed, the frequency of gene alterations, including mutations, fusions, amplifications, deep deletions, and multiple alterations ranged from 4.49% (8/178) to 10.87% (25/230), with mutations, amplifications, and deep deletions being the most commonly observed alterations ([Fig. 7A](#f7-or-0-0-7314){ref-type="fig"}). The percentages of genetic alterations in specific IGFBPs in NSCLC ranged from 0.6--2.3% (IGFBP1, 2.2; IGFBP2, 0.8%; IGFBP3, 2.3%; IGFBP4, 1.2; IGFBP5, 0.8%; IGFBP6, 0.6%; [Fig. 7B](#f7-or-0-0-7314){ref-type="fig"}), and were predominantly amplifications, deep deletions, and mutations; these were consistent with the results in [Fig. 7A](#f7-or-0-0-7314){ref-type="fig"}. The prognostic roles of IGFBPs in patients with NSCLC with or without alterations was analyzed, and no significant correlation between the presence of alterations and OS and disease-free survival (DFS) was observed (P=0.115 and P=0.700, respectively; [Fig. 7C and D](#f7-or-0-0-7314){ref-type="fig"}).

Next, GeneMANIA was used to construct a network of IGFBPs and their functionally related genes. The database identified 20 genes that were closely associated with IGFBPs. Additionally, all IGFBPs had a protein binding domain, and IGFBP3 and IGFBP4 were co-expressed, and colocalized within the cell ([Fig. 7E](#f7-or-0-0-7314){ref-type="fig"}).

### Enrichment analysis of IGFBPs in NSCLC

IGFBP functions were analyzed in DAVID, and 14 GO terms were enriched ([Table V](#tV-or-0-0-7314){ref-type="table"}). IGFBPs were enriched in the following biological processes (BP): Type B pancreatic cell proliferation, positive regulation of insulin-like growth factor receptor signaling pathway, regulation of glucose metabolic process, regulation of insulin-like growth factor receptor signaling pathway, regulation of cell growth, and negative regulation of smooth muscle cell migration. Molecular functions (MF) associated with IGFBPs were fibronectin binding, insulin-like growth factor II binding, and insulin-like growth factor I binding; cellular components (CC) associated with IGFBPs were the insulin-like growth factor ternary complex and the extracellular space. No KEGG pathways were enriched for IGFBPs.

Discussion
==========

### IGFBPs modulate cellular functions by both IGF-dependent and -independent mechanisms

IGF proteins regulate cellular proliferation, differentiation, apoptosis, and carcinogenesis, and IGFBPs modulate their signaling through IGF sequestration. The IGF-independent functions of IGFBPs depend on their interactions with many signaling pathways, which include both stimulatory and inhibitory cell-surface receptors such as the epidermal growth factor and transforming growth factor (TGF)-β receptors. In addition, IGFBPs regulate enzymes involved in sphingolipid metabolism. In this manner, IGFBPs can affect the balance between growth-inhibitory lipids, such as ceramides, and growth-stimulatory lipids, such as sphingosine-1-phosphate ([@b25-or-0-0-7314]). In the present study, a bioinformatics approach was used to examine the effects of these genes on NSCLC.

IGFBP1 mainly functions in the intracellular and pericellular compartments to regulate cell growth and survival ([@b25-or-0-0-7314]). It interacts with several proteins in addition to IGF ligands and plays an important role in the development and progression of several cancer types ([@b25-or-0-0-7314]--[@b28-or-0-0-7314]). An animal study revealed that IGFBP1 may function as a cell survival factor by suppressing TGFβ1 activation ([@b29-or-0-0-7314]). Sharma *et al* reported that elevated IGFBP1 levels were associated with unfavorable OS in prostate cancer ([@b30-or-0-0-7314]). Recently, however, Cao *et al* observed that low levels of IGFBP1 increased the risk of cancer ([@b31-or-0-0-7314]). However, in the present study, differential IGFBP1 expression was not observed between tumor and healthy tissues, but differential expression was observed in different tumor stages. High IGFBP1 mRNA was correlated with unfavorable OS in the total NSCLC cohort, who were followed for a 20-year period. High levels of IGFBP1 mRNA were also correlated with unfavorable OS in Ade but not in SCC.

IGFBP2, a critical mediator of crosstalk between several signaling pathways, is overexpressed in various cancer types, including breast, ovarian, gastric, and colorectal cancer, glioma, prostate cancer, leukemia, melanoma, rhabdomyosarcoma, as well as lung cancer ([@b32-or-0-0-7314]). High IGFBP2 expression was revealed to be associated with poor prognosis in lung cancer ([@b11-or-0-0-7314],[@b33-or-0-0-7314]). IGFBP2 has tumorigenic functions, and may act by regulating the phosphatase and tensin homolog (PTEN)-phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway ([@b33-or-0-0-7314]). However, conflicting results have also been reported. An *in vitro* study revealed that IGFBP2 suppressed the growth of various types of lung cancer tumors ([@b34-or-0-0-7314],[@b35-or-0-0-7314]). In this study, IGFBP2 expression was significantly upregulated in SCC tissues compared with normal tissues. Consistent with previous research, the present study revealed that high IGFBP2 mRNA expression was significantly associated with unfavorable OS in the total NSCLC cohort and patients with Ade specifically. However, high IGFBP2 mRNA levels were significantly correlated with favorable OS in patients with SCC. Thus, there is conflicting evidence as to whether IGFBP2 is oncogenic or tumor suppressive and its exact mechanism of action will require further investigation.

IGFBP3 was revealed to inhibit the mitogenic and antiapoptotic functions of IGF1 ([@b36-or-0-0-7314]). To date, many epidemiological studies have demonstrated that low IGFBP3 expression increases the incidence of cancer. In addition, IGFBP3 overexpression was revealed to inhibit NSCLC cell growth and tumorigenicity *in vivo* and *in vitro* ([@b37-or-0-0-7314]--[@b39-or-0-0-7314]). IGFBP3 inhibited angiogenesis in lung tumors by blocking the autocrine and paracrine loops of angiogenic factors ([@b40-or-0-0-7314]); targeting of IGFBP3 by miRNA-125b was associated with tumor invasion and poor patient outcomes in NSCLC ([@b41-or-0-0-7314]). Consistently, high plasma levels of IGFBP3 were revealed to be correlated with good prognosis in patients with advanced NSCLC ([@b42-or-0-0-7314]). These results indicated that circulating IGFBP3 levels may be a good prognostic marker in patients with NSCLC. In the present study, it was revealed that IGFBP3 mRNA expression was significantly higher in tumor tissues than in normal tissues, and it was significantly associated with unfavorable OS in patients with NSCLC. This could be attributed to differing regulation at the mRNA and protein level, thus further research would be helpful to explore the exact role of IGFBP3 in NSCLC.

Studies on IGFBP4 in NSCLC are limited. However, in epithelial ovarian tumors, IGFBP4 mRNA was highly expressed, but was not associated with OS in patients with cancer ([@b43-or-0-0-7314]). It was also observed that high IGFBP4 mRNA expression was significantly associated with unfavorable OS for all patients with NSCLC and patients with Ade but not SCC. However, differential IGFBP4 expression was not observed in tumor and healthy tissues.

As with IGFBP4, studies on IGFBP5 in NSCLC are limited. In breast cancer, IGFBP5 overexpression inhibited tumor growth ([@b44-or-0-0-7314]). However, the opposite occured in other cancer types; IGFBP5 increased IGF-dependent and -independent survival and proliferation in neuroblastoma and pancreatic cancer ([@b45-or-0-0-7314],[@b46-or-0-0-7314]). In the present study, differential IGFBP5 expression was not observed between tumor and healthy tissues, but high IGFBP5 levels were significantly correlated with favorable OS in patients with SCC. The differential effects of IGFBP5 may be attributed to the different microenvironments of specific tumors.

IGFBP6 appears to have an inhibitory effect on lung cancer. Consistent with a previous study, IGFBP6 expression was lower in cancerous lungs than in normal lungs ([@b47-or-0-0-7314]). A study by Sueoka *et al* indicated that IGFBP6 is a potent inducer of programmed cell death in NSCLC cells ([@b48-or-0-0-7314]). Koyama *et al* indicated that IGFBP6 mechanistically acted as an effector of the tumor suppressor semaphorin 3B in lung cancer ([@b49-or-0-0-7314]), and IGFBP6 was regulated by the important tumor suppressor tumor protein p53 ([@b50-or-0-0-7314]), and the molecular functions of IGFBPs in other tumors were partially related to p53 ([@b51-or-0-0-7314]--[@b53-or-0-0-7314]). However, in the present study, high IGFBP6 mRNA was not significantly associated with OS in patients with NSCLC, Ade, or SCC, presumably due to the TP53 status.

GEPIA was used to validate the prognostic value of IGFBP mRNA expression in NSCLC. However, the results were not completely consistent with the data from Kaplan-Meier analysis. This may be due to the smaller sample size in GEPIA. Thus, well designed studies with larger sample sizes should be performed in the future.

The correlation between IGFBP mRNA levels and other clinicopathological features was also evaluated. It was revealed that IGFBP1, IGFBP2, IGFBP3, and IGFBP4 were significantly associated with the smoking status of patients with NSCLC. Nicotine, which promotes NSCLC growth and metastasis, is responsible for 80% of all lung cancer cases ([@b54-or-0-0-7314]). Further studies will be required to investigate whether nicotine is directly related to aberrant IGFBP expression in NSCLC patients. Moreover, it was also revealed that high IGFBP1 and IGFBP4 mRNA levels were significantly correlated with unfavorable OS in patients with stage I NSCLC. High IGFBP2 and IGFBP4 mRNA expression levels were also associated with unfavorable OS in stage II patients. Additionally, *IGFBP5* was significantly associated with unfavorable OS in patients who did not receive chemotherapy.

As potential tumor suppressors and/or oncogenes, IGFBP mutations may be associated with carcinogenesis and cancer progression. Relatively consistent low levels of alterations were revealed in each IGFBP in NSCLC, but these alterations had no effect on OS or DFS, suggesting that these changes may not directly impact NSCLC prognosis. To further investigate the potential molecular mechanisms of IGFBPs in NSCLC, network analysis for each IGFBP was performed. The genes were mainly enriched in growth-related signaling pathways, highlighting their potential as targets for anti-NSCLC therapeutics.

In summary, the results indicated that high IGFBP1, IGFBP2, and IGFBP4 mRNA levels are associated with unfavorable OS in all patients with NSCLC, and especially those with Ade. Additionally, high IGFBP2 and IGFBP5 mRNA expression was significantly correlated with favorable OS in patients with SCC. Different IGFBPs were correlated with the smoking status, clinical stage, and chemotherapeutic regimen. These results highlight the heterogeneity and complexity of NSCLC signaling, and suggest that IGFBP-based tools for accurate prognosis prediction and targeted treatment strategies would be beneficial for patients with NSCLC. Further research is required to explore IGFBP gene expression at protein levels in different stages of lung cancer including lung adenocarcinoma and lung squamous cell carcinoma, and to pursue the exact molecular mechanisms of IGFBPs in NSCLC.
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![(A) The expression of IGFBPs in NSCLC patients. (B) The expression of IGFBPs in different stages of NSCLC. The threshold was based on the following parameters: P-value =0.01, fold-change =2, and data type: mRNA. IGFBPs, insulin-like growth factor-binding proteins; NSCLC, non-small cell lung cancer.](or-42-05-1981-g00){#f1-or-0-0-7314}

![Validation of IGFBPs at the protein level using the Human Protein Atlas database (IGFBP2, IGFBP3, and IGFBP5 were not available). IGFBP, insulin-like growth factor-binding protein.](or-42-05-1981-g01){#f2-or-0-0-7314}

![Correlation between IGFBP mRNA expression and OS in patients with NSCLC. OS curves of (A) IGFBP1 (Affymetrix IDs:205302_at), (B) IGFBP2 (Affymetrix IDs:202718_at), (C) IGFBP3 (Affymetrix IDs:210095_s\_at), (D) IGFBP4 (Affymetrix IDs:201508_at), (E) IGFBP5 (Affymetrix IDs:211959_at), and (F) IGFBP6 (Affymetrix IDs:203851_at). OS survival curves comparing patients with high (red) and low (black) IGFBP expression were plotted, with a threshold P-value of \<0.05. IGFBP, insulin-like growth factor-binding protein; OS, overall survival; NSCLC, non-small cell lung cancer.](or-42-05-1981-g02){#f3-or-0-0-7314}

![Correlation between IGFBP mRNA expression and OS in patients with Ade. OS curves of (A) IGFBP1 (Affymetrix IDs:205302_at), (B) IGFBP2 (Affymetrix IDs:202718_at), (C) IGFBP3 (Affymetrix IDs:210095_s\_at), (D) IGFBP4 (Affymetrix IDs:201508_at), (E) IGFBP5 (Affymetrix IDs:211959_at), and (F) IGFBP6 (Affymetrix IDs:203851_at). OS survival curves comparing patients with high (red) and low (black) IGFBP expression were plotted, with a threshold P-value of \<0.05. IGFBP, insulin-like growth factor-binding protein; OS, overall survival; Ade, adenocarcinoma.](or-42-05-1981-g03){#f4-or-0-0-7314}

![Correlation between IGFBP mRNA expression and OS in patients with SCC. OS curves of (A) IGFBP1 (Affymetrix IDs:205302_at), (B) IGFBP2 (Affymetrix IDs:202718_at), (C) IGFBP3 (Affymetrix IDs:210095_s\_at), (D) IGFBP4 (Affymetrix IDs:201508_at), (E) IGFBP5 (Affymetrix IDs:211959_at), and (F) IGFBP6 (Affymetrix IDs:203851_at). OS survival curves comparing patients with high (red) and low (black) IGFBP expression were plotted, with a threshold P-value of \<0.05. IGFBP, insulin-like growth factor-binding protein; OS, overall survival; SCC, squamous cell carcinoma.](or-42-05-1981-g04){#f5-or-0-0-7314}

![Validation of IGFBP prognostic values by GEPIA. OS curves for (A) IGFBP1, (B) IGFBP2, (C) IGFBP3, (D) IGFBP4, (E) IGFBP5, and (F) IGFBP6 in all cases of NSCLC. Survival curves marked as complete lines, and 95% confidence interval of survival curves marked as dotted lines. Red represents high expression and blue represents low expression. IGFBP, insulin-like growth factor-binding protein; GEPIA, Gene Expression Profiling Interactive Analysis; OS, overall survival; NSCLC, non-small cell lung cancer.](or-42-05-1981-g05){#f6-or-0-0-7314}

###### 

IGFBP alteration frequencies in NSCLC and IGFBP functional network. (A) Summary of IFGBP alterations. (B) OncoPrint visual summary of IGFBP alterations. (C) Kaplan-Meier plots comparing OS in cases with and without IGFBP gene alterations. (D) Kaplan-Meier plots comparing DFS in cases with and without IGFBP alterations. (E) Gene-gene interactions involving IGFBP family members. IGFBP, insulin-like growth factor-binding protein; NSCLC, non-small cell lung cancer; OS, overall survival; DFS, disease-free survival.
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###### 

Correlation between IGFBP mRNA level and OS in NSCLC patients with smoking status.

  *IGFBP* family   Smoking status   Cases   HR     95% CI       P-value
  ---------------- ---------------- ------- ------ ------------ -------------
  *IGFBP1*         Never smoked     205     1.62   0.91--2.88   0.097
                   smoked           820     1.38   1.12--1.7    **0.0025**
  *IGFBP2*         Never smoked     205     2.75   1.5--5.03    **0.00066**
                   smoked           820     1.09   0.89--1.34   0.41
  *IGFBP3*         Never smoked     205     1.76   0.99--3.12   **0.049**
                   smoked           820     0.98   0.8--1.21    0.87
  *IGFBP4*         Never smoked     205     2.7    1.47--4.95   **0.00083**
                   smoked           820     1.46   1.18--1.8    **0.00043**
  *IGFBP5*         Never smoked     205     1.64   0.92--2.9    0.087
                   smoked           820     0.97   0.79--1.19   0.76
  *IGFBP6*         Never smoked     205     1.48   0.84--2.6    0.18
                   smoked           820     1.01   0.82--1.24   0.91

Significant results are marked in bold. IGFBP, insulin-like growth factor-binding protein; OS, overall survival; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence intervals.

###### 

Correlation between IGFBP mRNA level and OS in NSCLC patients with clinical stages.

  *IGFBP* family   Clinical stages   Cases   HR     95% CI       P-value
  ---------------- ----------------- ------- ------ ------------ -------------
  *IGFBP1*         I                 577     1.65   1.26--2.17   **0.00027**
                   II                144     0.98   0.68--1.41   0.91
                   III               70      1.03   0.6--1.77    0.92
  *IGFBP2*         I                 577     1.94   1.47--2.57   **2.3e-06**
                   II                144     1.45   1-2.09       **0.047**
                   III               70      1.12   0.65--1.94   0.68
  *IGFBP3*         I                 577     1.06   0.81--1.39   0.68
                   II                144     1      0.69--1.44   1
                   III               70      1.2    0.69--2.08   0.53
  *IGFBP4*         I                 577     1.87   1.42--2.47   **6.9e-06**
                   II                144     2.13   1.47--3.09   **4.7e-05**
                   III               70      0.97   0.56--1.69   0.92
  *IGFBP5*         I                 577     1.23   0.94--1.62   0.13
                   II                144     0.94   0.65--1.35   0.72
                   III               70      0.97   0.56--1.66   0.9
  *IGFBP6*         I                 577     1.01   0.77--1.32   0.96
                   II                144     1.01   0.7--1.46    0.95
                   III               70      0.81   0.47--1.4    0.45

Significant results are marked in bold. IGFBP, insulin-like growth factor-binding protein; OS, overall survival; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence intervals.

###### 

Correlation between IGFBP mRNA level and OS in NSCLC patients with chemotherapy status.

  *IGFBP* family   Chemotherapy   Cases   HR     95% CI       P-value
  ---------------- -------------- ------- ------ ------------ ----------
  *IGFBP1*         No             310     1.38   0.99--1.93   0.06
                   Yes            176     0.81   0.53--1.22   0.31
  *IGFBP2*         No             310     1.03   0.74--1.43   0.88
                   Yes            176     1.24   0.82--1.86   0.3
  *IGFBP3*         No             310     1.39   0.99--1.94   0.055
                   Yes            176     1.28   0.85--1.93   0.23
  *IGFBP4*         No             310     1.18   0.85--1.65   0.33
                   Yes            176     1.16   0.77--1.75   0.48
  *IGFBP5*         No             310     1.42   1.01--1.98   **0.04**
                   Yes            176     0.86   0.57--1.3    0.48
  *IGFBP6*         No             310     1.05   0.75--1.46   0.78
                   Yes            176     1.24   0.82--1.85   0.3

Significant results are marked in bold. IGFBP, insulin-like growth factor-binding protein; OS, overall survival; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence intervals.

###### 

Correlation between IGFBP mRNA level and OS in NSCLC patients with different sex.

  *IGFBP* family   Sex      Cases   HR     95% CI       P-value
  ---------------- -------- ------- ------ ------------ -------------
  *IGFBP1*         Female   715     1.37   1.08--1.73   **0.0085**
                   Male     1,100   1.16   0.99--1.36   0.066
  *IGFBP2*         Female   715     1.1    0.88--1.39   0.4019
                   Male     1,100   1.3    1.11--1.52   **0.0012**
  *IGFBP3*         Female   715     1.04   0.82--1.31   0.77
                   Male     1,100   1.05   0.89--1.22   0.58
  *IGFBP4*         Female   715     1.32   1.05--1.67   **0.019**
                   Male     1,100   1.31   1.12--1.54   **0.00067**
  *IGFBP5*         Female   715     1.04   0.83--1.31   0.72
                   Male     1,100   1.02   0.87--1.2    0.79
  *IGFBP6*         Female   715     1.01   0.8--1.28    0.91
                   Male     1,100   0.87   0.75--1.02   0.095

Significant results are marked in bold. IGFBP, insulin-like growth factor-binding protein; OS, overall survival; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence intervals.

###### 

The GO function enrichment analysis of IGFBPs in NSCLC.

  Category           Term         Description                                                                    Count   P-value
  ------------------ ------------ ------------------------------------------------------------------------------ ------- -------------
  GOTERM_BP_DIRECT   GO:0044342   Type B pancreatic cell proliferation                                           3       1.98E-06
  GOTERM_BP_DIRECT   GO:0043568   Positive regulation of insulin-like growth factor receptor signaling pathway   3       4.74E-06
  GOTERM_BP_DIRECT   GO:0010906   Regulation of glucose metabolic process                                        3       1.58E-05
  GOTERM_BP_DIRECT   GO:0043567   Regulation of insulin-like growth factor receptor signaling pathway            6       2.37E-17
  GOTERM_BP_DIRECT   GO:0001558   Regulation of cell growth                                                      6       4.16E-14
  GOTERM_BP_DIRECT   GO:0014912   Negative regulation of smooth muscle cell migration                            2       0.002837913
  GOTERM_BP_DIRECT   GO:0014912   Negative regulation of smooth muscle cell migration                            2       0.002837913
  GOTERM_MF_DIRECT   GO:0001968   Fibronectin binding                                                            2       0.002150352
  GOTERM_MF_DIRECT   GO:0031995   Insulin-like growth factor II binding                                          6       3.40E-18
  GOTERM_MF_DIRECT   GO:0031994   Insulin-like growth factor I binding                                           6       3.40E-18
  GOTERM_CC_DIRECT   GO:0042567   Insulin-like growth factor ternary complex                                     2       0.001436265
  GOTERM_CC_DIRECT   GO:0005615   Extracellular space                                                            6       6.76E-07

GO, gene ontology; IGFBP, insulin-like growth factor-binding protein; NSCLC, non-small cell lung cancer; BP, biological processes; MF, molecular functions; CC, cellular components.
